Precision medicine for neurodevelopmental disorders

STALICLA is a clinical stage biotech company advancing the first clinically validated precision medicine platform for patients with Neurodevelopmental Disorders (NDDs), with a first application in ASD. STALICLA has already identified and validated several subgroups of patients with ASD and corresponding treatment candidates. STP1, tailored for the treatment of ASD-Phenotype 1, has successfully completed Phase 1b in early 2022, showing good safety/tolerability, positive target engagement, and superiority in cognition endpoints. In early 2023, STP1 will enter Phase 2; STP2, a phase 2 ready compound tailored for ASD-Phenotype 2 patients will also be entering Phase 2.
STALICLA is currently engaged in raising its Series B with a target amount of USD 65M to support its next stage of growth.